X-tosis Inc. has been awarded a $2.74 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support advancement of XTS-001, the lead candidate from the company’s Mitoxts platform, toward clinical development for the treatment of Parkinson’s disease. The grant will support confirmatory studies, biomarker development and IND-enabling work.

Replicate Bioscience Inc. has been awarded a new grant worth approximately $3 million from the Gates Foundation to accelerate the development of globally accessible tuberculosis (TB) vaccines using Replicate’s clinically validated self-replicating RNA (srRNA) platform.

Scribe Therapeutics Inc. has been awarded more than $25 million by California Institute for Regenerative Medicine (CIRM) across two preclinical programs for CRISPR-based gene editing therapies targeting cardiovascular and metabolic disease.